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We found evidence of ZIKV infection in amni-
otic epithelial cells and in fetal mesenchymal cells 
with affinity for perichondrium. Our observation 
indicates that ZIKV replicates in pluripotent (amni-
otic stem) cells involved in early-stage embryo de-
velopment. The observation of prolonged viremia 
until day 21 in the patient is in concordance with 
the findings of Driggers et al.3 and provides further 
data for consideration in the ongoing development 
of testing algorithms in pregnant women. These 
algorithms are currently based on the assumption 
that ZIKV viremia can be detected only up to 7 days.
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Cheyne–Stokes Respiration, Chemoreflex, and Ticagrelor-
Related Dyspnea
To the Editor: Dyspnea is a common side effect 
of the P2Y12-receptor antagonist ticagrelor in 
patients who receive this drug after an acute 
coronary syndrome.1,2 Symptoms develop in a 
dose-dependent fashion and usually disappear 
on discontinuation of ticagrelor and with reduc-
tions in plasma levels of the drug.1,2 The mecha-
nism of this side effect, which is unrelated to 
negative effects on cardiac and pulmonary func-
tion, is unknown.2
Here we describe the case of a patient (Pa-
tient 1) who was hospitalized for non–ST-seg-
ment elevation myocardial infarction. After the 
patient underwent complete revascularization for 
three-vessel coronary artery disease, double anti-
platelet therapy with aspirin and ticagrelor was 
initiated. Within a few hours after the adminis-
tration of ticagrelor, the patient began to report 
dyspnea, particularly at night and in the supine 
position, despite normal systolic and diastolic 
left ventricular function and normal pulmonary 
function. The results of the arterial blood gas 
analysis were normal, as were outcomes of pul-
monary function as assessed by spirometry, 
which was performed in conformity with the 
American Thoracic Society–European Respiratory 
Society standards and included measures of slow 
vital capacity, forced vital capacity, and forced 
expiratory volume in 1 second; static lung vol-
umes; and the diffusing capacity of the lung for 
carbon monoxide.
One month later, during a visit for persisting 
dyspnea, the patient was observed to have an 
abnormal pattern of periodic breathing, with 
alternating apneas and hyperventilation. Thus, 
24-hour cardiorespiratory monitoring was per-
formed. As shown in Figure 1A (top), this 
monitoring revealed the presence of Cheyne–
Stokes respiration (central apnea and hyper-
pnea), which occurred during both the night and 
the day. The rebreathing technique (i.e., a breath-
ing circuit in which exhaled air is inhaled with 
or without absorption of carbon dioxide or oxy-
gen) also showed increased chemosensitivity to 
hypercapnia (Fig. 1A, middle) and normal che-
mosensitivity to hypoxia.3
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Immediately after the patient discontinued 
ticagrelor and switched to clopidogrel, the dys-
pnea attenuated and then disappeared. Serial 
evaluations of the patient’s breathing pattern 
and chemosensitivity performed at 1 week and 
at 1 month after discontinuation of ticagrelor 
showed a progressive reduction, to normal val-
ues, of both the apnea–hypopnea index (AHI, the 
number of occurrences of apnea or hypopnea 
per hour) (Fig. 1B, top, and 1C, top) and chemo-
sensitivity to hypercapnia (Fig. 1B, middle, and 
1C, middle).
The same respiratory pattern was confirmed 
in three other patients who had normal cardio-
pulmonary function and who were screened for 
Cheyne–Stokes respiration 1 month after an 
acute coronary syndrome. In Patient 2, the diur-
nal AHI was 28 and the nocturnal AHI was 48. 
In Patient 3, the diurnal AHI was 41 and the 
nocturnal AHI 74, and in Patient 4, the diurnal 
AHI was 30 and the nocturnal AHI 58. In these 
three patients, ticagrelor was continued on the 
basis of a clinical decision, and in two patients, 
the follow-up confirmed the persistence of 
Cheyne–Stokes respiration. In Patient 2, the diur-
nal AHI after 1 week was 3 and the nocturnal 
AHI 35; in Patient 3, the diurnal AHI after 1 month 
was 13 and the nocturnal AHI 59.
Figure 1. Results of 24-Hour Cardiorespiratory Monitoring and Chemosensitivity to Carbon Dioxide in Patient 1.
One month after the initiation of ticagrelor, Patient 1 had evidence of Cheyne–Stokes respiration (Panel A [top]). Diurnal and nocturnal 
scores on the apnea–hypopnea index (AHI, the number of occurrences of apnea or hypopnea per hour) are shown. The patient also had 
increased chemosensitivity to carbon dioxide while receiving ticagrelor (Panel A, middle and bottom). After discontinuation of the drug, 
the amelioration of symptoms occurred with progressive disappearance of Cheyne–Stokes respiration (Panels B, top, and C, top) and a 
reduction in chemoreflex sensitivity to hypercapnia (Panels B, middle and bottom, and C, middle and bottom). AU denotes arbitrary 
units, HCVR hypercapnic ventilatory response, PetCO2 partial pressure of end-tidal carbon dioxide, and SaO2 arterial oxygen saturation.
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The P2Y12 receptor is expressed not only in 
platelets but also in other hematopoietic and 
nonhematopoietic cells, including microglia in 
the central nervous system,4 with potential puri-
nergic stimulation of the chemoreflex system.5 
This stimulation may elicit Cheyne–Stokes respi-
ration. In a patient who receives ticagrelor and 
has persistent dyspnea, screening for Cheyne–
Stokes respiration may be considered to address 
the patient’s discomfort.
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